Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS Study

Purpose: To compare Hybrid Capture It (HC2) in detecting high-risk (HR) HPV in patient-collected vaginal samples with those obtained using gynaecologist collected samples. Methods: Patients were submitted to Pap smears, Visual inspection with acetic acid (VIA) and HC2 for hr-HPV. Results: A total of 1,081 HC2 tests for HR-HPV were performed: 770 (71.2%) samples were collected by a physician and 311 (28.8%) were self-collected by the patients. In detecting any cervical lesion, the sensitivity of HC2 collected by a physician was higher (92.86%) than that (37.5%) in the self-sampling group. Negative predictive value (NPV) was high for both, 99.69% and 93.75%, respectively. Using the CIN2 cutoff, performance of HC2 was significantly improved: 92.9% and 62.5%, respectively. HC2 specificity for an), cervical lesion and for CIN2 or higher were close to 90% in both groups. Conclusions: Self-sampled HPV testing is a powerful option to increase the detection of cervical lesions in women segregated from prevention programs.

Hybrid capture; HPV; Cervical cancer; Liquid based cytology; Self-sampling

[1] Burchell A.N., Winer R.L., de Sanjose S., Franco E.L.: “Chapter 6: Epidemiology and transmission dynamics of genital HPV infection”. Vaccine, 2006, 24 (suppl. 3), S52.

[2] Villa L.L.: “CHAPTER 1 Biology of genital human papillomaviruses”. Int. J. Gynaecol. Obstet., 2006, 94 (suppl. 1), S3.

[3] Holanda F. Jr., Castelo A., Veras T.M., de Almeida F.M., Lins M.Z., Dores G.B.: “Int. J. Primary screening for cervical cancer through self sampling”. Gynaecol. Obstet., 2006, 95, 179.

[4] Stenvall H., Wikstrom I., Backlund I., Wilander E.: “Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device”. Acta Obstet. Gynecol. Scand., 2007, 86, 16.

[5] Moscicki A.B., Schiffman M., Kjaer S., Villa L.L.: “Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine”, 2006, 24 (suppl. 3), S42.

[6] FDA news. FDA approves expanded use of HPV Test. March 31, 2003. www.fda.gov/bbs/topics/news/2003/new00890.html

[7] Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G. et al.: “American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors”. C.A. Cancer J. Clin., 2007, 57, 7.

[8] Hillemanns P., Kimmig R., Hüttemann U., Dannecker C., Thaler C.J.: “Screening for cervical neoplasia by self-assessment for human papillomavirus DNA”. Lancet, 1999, 354, 1970.

[9] Wright T.C., Denny L., Kuhn L., Pollack A., Lorincz A.: “HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer”. JAMA, 2000, 283, 81.

[10] Szarewski A., Cadman L., Mallett S., Austin J., Londesborough P., Waller J. et al.: “Human papillomavirus testing by self-sampling: assessment of accuracy in anunsupervised clinical setting”. J. Med. Screen., 2007, 14, 34.

[11] Petignat P., Faltin D.L., Bruchim I., Tramer M.R., Franco E.L., Coutlee F.: “Are self-collected samples comparable to physiciancollected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis”. Gynecol. Oncol., 2007, 105, 530.

[12] Waller J., McCaffery K., Forrest S., Szarewski A., Cadman L., Austin J., Wardle J.: “Acceptability of unsupervised HPV selfsampling using written instructions”. J. Med. Screen., 2006, 13, 208.

[13] Dannecker C., Siebert U., Thaler C.J., Kiermeir D., Hepp H., Hillemanns P.: “Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics”. Ann. Oncol., 2004, 15, 863.

[14] Kahn J.A.: “Self-testing for human papillomavirus using a vaginal swab: placing prevention of cervical cancer in the patient’s hands”. Ann. Oncol., 2004, 15, 847.

[15] Syrjanen K., Naud P., Derchain S., Roteli-Martins C., Longatto- Filho A., Tatti S. et al.: “Comparing Pap smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study”. Anticancer Res., 2005, 25, 3469.

[16] Scully R.E., Bonfiglio T.A., Silverberg S.G., Wilkinson E.J.: “World Health Organization International Classification of Tumours. Histological Typing of Female Genital Tract Tumours”. 2nd edition, Berlin, Springer-Verlag, 1994.

[17] Tavassoli F.A., Deville P.: “Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours”. Lyon, IARC Press, 2003.

[18] Cox J.T., Lorincz A.T., Schiffman M.H., Sherman M.E., Cullen A., Kurman R.J.: “Human papillomavirus testing by hybrid capture appears to be useful in triaging women with cytologic diagnosis of atypical squamous cells of undetermined significance”. Am. J. Obstet. Gynecol., 1995, 172, 946.

[19] Howard M., Sellors J., Kaczorowski J., Lorincz A.: “Optimal cuttoff of the hybrid capture II human papillomavirus test for selfcollected vaginal, vulvar, and urine specimens in a colposcopy referral population”. J. Lower Genital Tract. Dis., 2004, 8, 33.

[20] Doorbar J.: “Molecular biology of human papillomavirus infection and cervical cancer”. Clin. Sci (Lond), 2006, 110, 525.

[21] Longworth M.S., Laimins L.A.: “Pathogenesis of human papillomaviruses in differentiating epithelia”. Microbiol. Mol. Biol. Rev., 2004, 68, 362.

[22] Goldie S.: “CHAPTER 10 A public health approach to cervical cancer control: Considerations of screening and vaccination strategies”. Int. J. Gynaecol. Obstet., 2006, 94 (suppl. 1), S95.

[23] Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S. et al.: “Overview of the European and North American studies on HPV testing in primary cervical cancer screening”. Int. J. Cancer, 2006, 1095.

[24] Nanda K., McCroy D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., Matchar D.B.: “Accuracy of the Papanicolaou test in screening for and follow up of cervical cytoogic abnormalities: a systematic review”. Ann. Intern. Med., 2000, 132, 810.

[25] Witt A., Hudelist G., Gregor H., Kucera E., Walchetseder C.: “Czerwenka. The detection of HPV DNA improves the recognition of cervical intraepithelial lesions”. Arch. Gynecol. Obstet., 2003, 268, 29.

[26] Arbyn M., Buntinx F., Ranst M.V., Paraskevaidis E., Martin- Hirsch P., Dillner J.: “Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia”. JNCI, 2004, 96, 280.

[27] Longatto-Filho A., Erzen M., Branca M., Roteli-Martins C., Naud P., Derchain S.F., Hammes L., Sarian L.O., Braganca J.F., Matos J., Gontijo R., Lima T., Maeda M.Y., Tatti S., Syrjanen S., Dores G., Lorincz A., Syrjanen K.: “Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study”. Int. J. Gynecol. Cancer, 2006, 16, 955.

[28] Goldie S.J., Kuhn L., Denny L., Pollack A., Wright T.C.: “Policy Analysis of cervical cancer screening strategies in low-resourse settings”. JAMA, 2001, 285, 3107.

[29] Goldie S.J., Kim J.J., Wright T.C.: “Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more”. Obstet. Gynecol., 2004, 103, 619.

[30] Kanh L., Denny L., Pollack A., Lorincz A., Richart R.M., Wright T.C.: “Human papillomavirus DNA testing for cervical cancer screening in low-resource settings”. J. Natl. Cancer Inst., 2000, 17, 92, 818.

[31] Kuhn L., Denny L., Pollack A., Lorincz A., Richart R.M., Wright T.C.: “Human papillomavirus DNA testing for cervical cancer screening in low-resource settings”. J. Natl. Cancer Inst., 2000, 92, 818.

[32] Gontijo R.C., Derchain S.F., Roteli-Martins C., Braganca J.F., Sarian L.O., Morais S.S. et al.: “Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2006, 133, 239.

[33] Sarian L.O., Derchain S.F., Naud P., Roteli-Martins C., Longatto- Filho A., Tatti S. et al.: “Evaluation of visual inspection with acetic acid (VIA), Lugol’s iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study”. J. Med. Screen, 2005, 12, 142.

[34] Clavel C., Cucherousset J., Lorenzato M., Caudroy S., Nou J.M., Nazeyrollas P. et al.: “Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions”. Br. J. Cancer, 2004, 90, 1803.

[35] Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E., Glass A.G. et al.: “Human Papillomavirus testing, and risk for cervical neoplasia: A 10-year Cohort Analysis”. Journal of the National Cancer Institute, 2003, 95, 46.

[36] Kjaer S., Hogdall E., Frederiksen K., Munk C., van den Brule A., Svare E. et al.: “The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period”. Cancer Res., 2006, 66, 10630.

[37] Girianelli V.R., Thuler L.C., Szklo M., Donato A., Zardo L.M., Lozana J.A. et al.: “Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer”. Eur. J. Cancer Prev., 2006, 15, 504.

[38] Herrington C.S.: “Self testing for human papillomaviruses”. J. Clin. Pathol., 200, 55, 408.

[39] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Jaspars L.H., Voorhorst F.J. et al.: “Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women”. J. Clin. Pathol., 2002, 55, 435.